Tag : atherosclerosis

Latest News

VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin

Newsemia
Adding clopidogrel added no efficacy but caused additional bleeding episodes. Source link...
Latest News

The association between anthropometric measures of adiposity and the progression of carotid atherosclerosis

Newsemia
Imahori, Y; Mathiesen, EB; Morgan, KE; Frost, C; Hughes, AD; Hopstock, LA; Johnsen, SH; … Leon, DA; + view all Imahori, Y; Mathiesen, EB; Morgan,...
Cardiology

Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.

Newsemia
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5...
Latest News

Sophisticated genetic tests are not notably better than traditional risk factors at predicting heart disease

Newsemia
Traditional cardiovascular risk factors often assessed in an annual physical, such as blood pressure, cholesterol levels, diabetes, and smoking status, are at least as valuable...
Latest News

Global Atherosclerosis Drugs Market Drivers, Restraints & Opportunities During the Forecast Period, 2019-2027 – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Atherosclerosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 – 2027” report has been added to ResearchAndMarkets.com’s offering....
Latest News

NHS partners with pharma giant to trial a twice-a-year jab to lower cholesterol levels

Newsemia
Cardiovascular disease, including heart disease and stroke, are among the top killers worldwide. Ischemic heart disease and stroke are the world’s major killers, accounting for...
Neurology

Unmet LDL-C Goals Common in ASCVD: PINNACLE, NHANES

Newsemia
Two studies of patients with ASCVD — NHANES and the PINNACLE registry — show ‘a large burden of non- and undertreatment’ and ‘room for improvement’...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy